‘Trust Stamp’ Vaccine Record And Payment System To Be Tested On Low-Income Africans

A biometric digital identity platform that “evolves just as you evolve” is set to be introduced in “low-income, remote communities” in West Africa thanks to a public-private partnership between the Bill Gates-backed GAVI vaccine alliance, Mastercard and the AI-powered “identity authentication” company, Trust Stamp.

The program, which was first launched in late 2018, will see Trust Stamp’s digital identity platform integrated into the GAVI-Mastercard “Wellness Pass,” a digital vaccination record and identity system that is also linked to Mastercard’s click-to-play system that powered by its AI and machine learning technology called NuData. Mastercard, in addition to professing its commitment to promoting “centralized record keeping of childhood immunization” also describes itself as a leader toward a “World Beyond Cash,” and its partnership with GAVI marks a novel approach towards linking a biometric digital identity system, vaccination records, and a payment system into a single cohesive platform. The effort, since its launch nearly two years ago, has been funded via $3.8 million in GAVI donor funds in addition to a matched donation of the same amount by the Bill and Melinda Gates Foundation.

In early June, GAVI reported that Mastercard’s Wellness Pass program would be adapted in response to the coronavirus (COVID-19) pandemic. Around a month later, Mastercard announced that Trust Stamp’s biometric identity platform would be integrated into Wellness Pass as Trust Stamp’s system is capable of providing biometric identity in areas of the world lacking internet access or cellular connectivity and also does not require knowledge of an individual’s legal name or identity to function. The Wellness Program involving GAVI, Mastercard, and Trust Stamp will soon be launched in West Africa and will be coupled with a Covid-19 vaccination program once a vaccine becomes available.

Read more: ‘Trust Stamp’ Vaccine Record And Payment System To Be Tested On Low-Income Africans